Literature DB >> 24412360

Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4.

Ravshan Burikhanov1, Tripti Shrestha-Bhattarai2, Nikhil Hebbar2, Shirley Qiu3, Yanming Zhao2, Gerard P Zambetti4, Vivek M Rangnekar5.   

Abstract

The guardian of the genome, p53, is often mutated in cancer and may contribute to therapeutic resistance. Given that p53 is intact and functional in normal tissues, we harnessed its potential to inhibit the growth of p53-deficient cancer cells. Specific activation of p53 in normal fibroblasts selectively induced apoptosis in p53-deficient cancer cells. This paracrine effect was mediated by p53-dependent secretion of the tumor suppressor Par-4. Accordingly, the activation of p53 in normal mice, but not p53(-)/(-) or Par-4(-)/(-) mice, caused systemic elevation of Par-4, which induced apoptosis of p53-deficient tumor cells. Mechanistically, p53 induced Par-4 secretion by suppressing the expression of its binding partner, UACA, which sequesters Par-4. Thus, normal cells can be empowered by p53 activation to induce Par-4 secretion for the inhibition of therapy-resistant tumors.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24412360      PMCID: PMC3922895          DOI: 10.1016/j.celrep.2013.12.020

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  20 in total

Review 1.  Current strategies to target p53 in cancer.

Authors:  Fang Chen; Wenge Wang; Wafik S El-Deiry
Journal:  Biochem Pharmacol       Date:  2010-05-05       Impact factor: 5.858

2.  Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD).

Authors:  Guanghu Wang; Michael Dinkins; Qian He; Gu Zhu; Christophe Poirier; Andrew Campbell; Margot Mayer-Proschel; Erhard Bieberich
Journal:  J Biol Chem       Date:  2012-04-24       Impact factor: 5.157

3.  The regulation of the endosomal compartment by p53 the tumor suppressor gene.

Authors:  Xin Yu; Todd Riley; Arnold J Levine
Journal:  FEBS J       Date:  2009-03-03       Impact factor: 5.542

4.  Systemic Par-4 inhibits non-autochthonous tumor growth.

Authors:  Yanming Zhao; Ravshan Burikhanov; Jason Brandon; Shirley Qiu; Brent J Shelton; Brett Spear; Subbarao Bondada; Scott Bryson; Vivek M Rangnekar
Journal:  Cancer Biol Ther       Date:  2011-07-15       Impact factor: 4.742

5.  "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally.

Authors:  Isabel García-Cao; Marta García-Cao; Juan Martín-Caballero; Luis M Criado; Peter Klatt; Juana M Flores; Jean-Claude Weill; María A Blasco; Manuel Serrano
Journal:  EMBO J       Date:  2002-11-15       Impact factor: 11.598

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

7.  Identification of a novel autoantigen UACA in patients with panuveitis.

Authors:  K Yamada; S Senju; T Nakatsura; Y Murata; M Ishihara; S Nakamura; S Ohno; A Negi; Y Nishimura
Journal:  Biochem Biophys Res Commun       Date:  2001-02-02       Impact factor: 3.575

8.  Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4.

Authors:  Ravshan Burikhanov; Tripti Shrestha-Bhattarai; Shirley Qiu; Nidhi Shukla; Nikhil Hebbar; Subodh M Lele; Craig Horbinski; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2012-11-30       Impact factor: 12.701

9.  Nutlin-3 inhibits the NFkappaB pathway in a p53-dependent manner: implications in lung cancer therapy.

Authors:  Anwesha Dey; E T Wong; P Bist; V Tergaonkar; David P Lane
Journal:  Cell Cycle       Date:  2007-06-27       Impact factor: 4.534

10.  In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Authors:  Lyubomir T Vassilev; Binh T Vu; Bradford Graves; Daisy Carvajal; Frank Podlaski; Zoran Filipovic; Norman Kong; Ursula Kammlott; Christine Lukacs; Christian Klein; Nader Fotouhi; Emily A Liu
Journal:  Science       Date:  2004-01-02       Impact factor: 47.728

View more
  18 in total

1.  4th international conference on tumor progression and therapeutic resistance: meeting report.

Authors:  Varun V Prabhu; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors.

Authors:  Nikhil Hebbar; Ravshan Burikhanov; Nidhi Shukla; Shirley Qiu; Yanming Zhao; Kojo S J Elenitoba-Johnson; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2017-06-16       Impact factor: 12.701

3.  PAWR-mediated suppression of BCL2 promotes switching of 3-azido withaferin A (3-AWA)-induced autophagy to apoptosis in prostate cancer cells.

Authors:  Bilal Rah; Reyaz ur Rasool; Debasis Nayak; Syed Khalid Yousuf; Debaraj Mukherjee; Lekha Dinesh Kumar; Anindya Goswami
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

Review 4.  A journey beyond apoptosis: new enigma of controlling metastasis by pro-apoptotic Par-4.

Authors:  Reyaz Ur Rasool; Debasis Nayak; Souneek Chakraborty; Archana Katoch; Mir Mohd Faheem; Hina Amin; Anindya Goswami
Journal:  Clin Exp Metastasis       Date:  2016-08-27       Impact factor: 5.150

5.  Development of 6H-Chromeno[3,4-c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones as Par-4 Secretagogues.

Authors:  Mykhaylo S Frasinyuk; Svitlana P Bondarenko; Vitaliy M Sviripa; Ravshan Burikhanov; Vivek M Rangnekar; Chunming Liu; David S Watt
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

6.  Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.

Authors:  Mary K McKenna; Sunil K Noothi; Sara S Alhakeem; Karine Z Oben; Joseph T Greene; Rajeswaran Mani; Kathryn L Perry; James P Collard; Jacqueline R Rivas; Gerhard C Hildebrandt; Roger A Fleischman; Eric B Durbin; John C Byrd; Chi Wang; Natarajan Muthusamy; Vivek M Rangnekar; Subbarao Bondada
Journal:  Blood       Date:  2018-04-25       Impact factor: 22.113

Review 7.  Dysregulation of lysophospholipid signaling by p53 in malignant cells and the tumor microenvironment.

Authors:  Sue Chin Lee; Kuan-Hung Lin; Andrea Balogh; Derek D Norman; Mitul Bavaria; Bryan Kuo; Junming Yue; Louisa Balázs; Zoltán Benyó; Gábor Tigyi
Journal:  Cell Signal       Date:  2020-11-28       Impact factor: 4.315

8.  Inhibition of AKT promotes FOXO3a-dependent apoptosis in prostate cancer.

Authors:  T P Das; S Suman; H Alatassi; M K Ankem; C Damodaran
Journal:  Cell Death Dis       Date:  2016-02-25       Impact factor: 8.469

9.  Arylquins target vimentin to trigger Par-4 secretion for tumor cell apoptosis.

Authors:  Ravshan Burikhanov; Vitaliy M Sviripa; Nikhil Hebbar; Wen Zhang; W John Layton; Adel Hamza; Chang-Guo Zhan; David S Watt; Chunming Liu; Vivek M Rangnekar
Journal:  Nat Chem Biol       Date:  2014-09-14       Impact factor: 15.040

10.  Engrailed Homeoprotein Protects Mesencephalic Dopaminergic Neurons from Oxidative Stress.

Authors:  Hocine Rekaik; François-Xavier Blaudin de Thé; Julia Fuchs; Olivia Massiani-Beaudoin; Alain Prochiantz; Rajiv L Joshi
Journal:  Cell Rep       Date:  2015-09-24       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.